Limit search to available items
Nearby Subjects are:
Result Page   Prev Next
Add Marked to Bag Add All On Page Add Marked to My Lists
Mark   Year Entries
 

Drug Error, High-Alert -- See Medication Errors


Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or the indicated proper drug dosage
  1
 

Drug errors -- See Medication errors


  1
 

Drug Eruption -- See Drug Eruptions


Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions
  1
 

Drug Eruption, Maculopapular -- See Drug Eruptions


Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions
  1
 

Drug-eruptions -- See Drug-exanthems


  1
Drug Eruptions   9
Drug Eruptions -- etiology : Drug eruptions Haur Yueh Lee, Daniel Creamer, editors  2022 1
 

Drug Eruptions, Maculopapular -- See Drug Eruptions


Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions
  1
 

Drug Evaluation -- See Also Clinical Trials as Topic


Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
  1
Drug Evaluation   69
Drug Evaluation -- ethics   3
 

Drug Evaluation, FDA Phase 1 -- See Clinical Trials, Phase I as Topic


Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase 2 as Topic -- See Clinical Trials, Phase II as Topic


Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase 3 as Topic -- See Clinical Trials, Phase III as Topic


Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase 4 as Topic -- See Clinical Trials, Phase IV as Topic


Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase I -- See Clinical Trials, Phase I as Topic


Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase I as Topic -- See Clinical Trials, Phase I as Topic


Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase II as Topic -- See Clinical Trials, Phase II as Topic


Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase III as Topic -- See Clinical Trials, Phase III as Topic


Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries
  1
 

Drug Evaluation, FDA Phase IV as Topic -- See Clinical Trials, Phase IV as Topic


Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries
  1
Drug Evaluation -- history : The quest for cortisone / Thom Rooke  2012 1
Drug Evaluation -- legislation & jurisprudence   2
Drug Evaluation -- methods   30
Drug Evaluation -- Periodicals : Expert opinion on drug safety (Online)  2002- 1
 

Drug Evaluation, Preclinical -- See Also Toxicity Tests


An array of tests used to determine the toxicity of a substance to living systems. These include tests on clinical drugs, foods, and environmental pollutants
  1
Drug Evaluation, Preclinical.   40
Drug Evaluation, Preclinical -- instrumentation : Assay and drug development technologies (Online)  2002- 1
Drug Evaluation, Preclinical -- methods   25
Drug Evaluation, Preclinical -- standards   6
Drug Evaluation -- standards.   11
 

Drug Evaluation Studies -- See Drug Evaluation


Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals
  1
 

Drug Evaluation Studies, Preclinical -- See Drug Evaluation, Preclinical


Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications
  1
 

Drug Evaluation Study -- See Drug Evaluation


Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals
  1
Drug Evaluation -- trends : Drug Efficacy, Safety, and Biologics Discovery : Emerging Technologies and Tools / edited by Sean Ekins, Jinghai J. Xu  2009 1
Drug Evaluation -- veterinary.   2
 

Drug Evaluations -- See Drug Evaluation


Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals
  1
 

Drug Evaluations, Preclinical -- See Drug Evaluation, Preclinical


Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications
  1
  Drug Event, Adverse -- 2 Related Subjects   2
  Drug Events, Adverse -- 2 Related Subjects   2
Drug-exanthems.   9
Drug-exanthems -- Diagnosis : Cutaneous drug eruptions : diagnosis, histopathology and therapy / John C. Hall, Brian J. Hall, editors  2015 1
Drug-exanthems -- Handbooks, manuals, etc   4
Drug-exanthems -- Periodicals : Dermatitis (Online)    1
Drug-exanthems -- Treatment : Cutaneous drug eruptions : diagnosis, histopathology and therapy / John C. Hall, Brian J. Hall, editors  2015 1
Drug factories.   4
Drug factories -- Australia -- Periodicals. : Annual report  1991- 1
Drug factories -- Design and construction : Pharmaceutical production facilities : design and applications / Graham Cole  1998 1
Drug factories -- Environmental aspects : Methamphetamine laboratories / Paul V. Ardus, editor  2011 1
Drug factories -- Environmental aspects -- United States : Methamphetamine laboratories / Paul V. Ardus, editor  2011 1
Drug factories -- Equipment and supplies -- Cleaning -- Handbooks, manuals, etc : Cleaning Validation Manual : a Comprehensive Guide for the Pharmaceutical and Biotechnology Industries  2010 1
Add Marked to Bag Add All On Page Add Marked to My Lists
Result Page   Prev Next